New Compound AP503 Strengthens Bones and Combats Osteoporosis in Mice
- Researchers at Leipzig University have identified an experimental compound called AP503 that significantly strengthens bones in mice by activating GPR133.
- The investigation reveals that GPR133 belongs to a largely underexplored family of adhesion G protein-coupled receptors essential for maintaining skeletal integrity.
- Within skeletal tissue, GPR133 is triggered by mechanical strain and interactions between neighboring cells.
Leipzig Researchers Target GPR133 to Combat Bone Degradation
Researchers at Leipzig University have identified an experimental compound called AP503 that significantly strengthens bones in mice by activating GPR133. Unveiled in a study published on June 30, 2025, in the journal Signal Transduction and Targeted Therapy, the newly uncovered receptor plays a vital role in boosting bone formation while simultaneously slowing bone loss.
The investigation reveals that GPR133 belongs to a largely underexplored family of adhesion G protein-coupled receptors essential for maintaining skeletal integrity. Professor Ines Liebscher, lead investigator of the study from the Rudolf Schönheimer Institute of Biochemistry at the Faculty of Medicine, explained that genetic impairments in this receptor lead to early signs of diminished bone density comparable to human osteoporosis. When researchers administered AP503—a substance recently identified through a computer-assisted screen as a stimulator of GPR133—they observed a substantial increase in bone strength across both healthy and osteoporotic mice.
Mechanics of Skeletal Renewal and AP503 Stimulation
Within skeletal tissue, GPR133 is triggered by mechanical strain and interactions between neighboring cells. This activation initiates a signaling cascade that elevates the activity of bone-building cells known as osteoblasts while suppressing bone-breaking cells called osteoclasts. By replicating this natural signaling process, AP503 offers a targeted mechanism to rebuild bone density, presenting a potential therapeutic option for postmenopausal women and others vulnerable to long-term bone degradation.
Addressing Osteoporosis Demands in Germany and Beyond
The discovery of the bone-strengthening pathway arrives amid a high demand for long-term treatments that prevent bone loss with minimal side effects. In Germany alone, osteoporosis impacts approximately six million individuals, with women making up the vast majority of cases.
Dual Impact on Skeletal Muscle and Aging Populations
Building on prior findings that showed AP503 also strengthens skeletal muscle, the Leipzig team highlights the compound’s dual impact on bones and muscles as a promising avenue for addressing age-related physical decline.
Dr Juliane Lehmann, lead author of the study at the Rudolf Schönheimer Institute of Biochemistry, noted that the parallel strengthening of bone and muscle underscores the receptor’s broad potential for future medical applications in aging populations. The research builds on more than a decade of specialized study into adhesion G protein-coupled receptors at Leipzig University, conducted within Collaborative Research Centre 1423 on the structural dynamics of GPCR activation and signaling.
Next Steps in Preclinical Evaluation
Following the recent publication of these preclinical findings, the research team at Leipzig University is actively pursuing follow-up projects. These upcoming investigations aim to evaluate the efficacy of AP503 across various disease models and to examine the broader physiological functions of GPR133 throughout the body.